Medline (NASDAQ:MDLN) Stock Price Target Raised at Barclays

Medline logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays raised Medline’s price target from $43 to $45 and maintained an “overweight” rating, implying about 19% upside from the prior close.
  • Analyst sentiment is broadly positive: 23 analysts rate the stock Buy, five Hold and one Sell, with a consensus “Moderate Buy” rating and a $46.15 average price target.
  • Medline reported quarterly EPS of $0.44, beating the $0.32 consensus estimate; revenue was $7.86 billion.
  • MarketBeat previews top five stocks to own in December.

Medline (NASDAQ:MDLN - Get Free Report) had its price target hoisted by equities research analysts at Barclays from $43.00 to $45.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Barclays's price objective suggests a potential upside of 19.01% from the stock's previous close.

A number of other equities research analysts have also commented on MDLN. Truist Financial lowered their price target on shares of Medline from $56.00 to $47.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Zacks Research raised shares of Medline from a "strong sell" rating to a "hold" rating in a report on Wednesday. Evercore set a $39.00 price objective on shares of Medline in a research report on Thursday, August 6th. Stifel Nicolaus lowered their price objective on shares of Medline from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Finally, Citigroup upped their price objective on shares of Medline from $45.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.15.

View Our Latest Analysis on MDLN

Medline Trading Down 0.1%

MDLN stock traded down $0.03 during midday trading on Friday, hitting $37.81. The company had a trading volume of 503,036 shares, compared to its average volume of 7,925,196. The company has a current ratio of 4.04, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. Medline has a 52 week low of $31.37 and a 52 week high of $50.88. The stock's 50 day moving average price is $35.60 and its 200 day moving average price is $39.25. The stock has a market cap of $49.74 billion and a price-to-earnings ratio of 86.44.

Medline (NASDAQ:MDLN - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The firm had revenue of $7.86 billion during the quarter. As a group, equities research analysts expect that Medline will post 1.58 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of the company's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares in the company, valued at $715,182,924.05. This represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 6,348,676 shares of company stock worth $224,525,137 over the last 90 days. 0.81% of the stock is currently owned by insiders.

Institutional Trading of Medline

Several large investors have recently added to or reduced their stakes in MDLN. Healthcare of Ontario Pension Plan Trust Fund increased its position in Medline by 233.3% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company's stock valued at $222,500,000 after purchasing an additional 3,500,000 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Medline by 30,255.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company's stock worth $94,353,000 after purchasing an additional 2,691,529 shares during the period. Durable Capital Partners LP lifted its position in shares of Medline by 80.2% in the 3rd quarter. Durable Capital Partners LP now owns 4,734,627 shares of the company's stock worth $164,292,000 after purchasing an additional 2,107,306 shares during the period. Worldquant Millennium Advisors LLC boosted its stake in shares of Medline by 144.6% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 2,647,660 shares of the company's stock valued at $91,874,000 after purchasing an additional 1,565,422 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Medline during the 2nd quarter valued at about $40,430,000.

Medline Company Profile

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

See Also

Analyst Recommendations for Medline (NASDAQ:MDLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medline Right Now?

Before you consider Medline, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medline wasn't on the list.

While Medline currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines